Guardant Health CCO granted 18,744 RSUs

Freeman Chris reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Freeman Chris reported acquisition or exercise transactions in this Form 4 filing.

Guardant Health, Inc. reported that Chief Commercial Officer Chris Freeman received a grant of 18,744 restricted stock units. These RSUs, which represent rights to receive an equal number of common shares, were awarded as compensation and involve no cash purchase or market trade.

The award granted on March 11, 2026 vests over three years: 33% of the units vest on April 1, 2027, with the remaining 67% vesting in equal quarterly installments over the following two years. After this grant, Freeman holds 18,744 RSUs directly.

Insider Trade Summary

Grant/Award: 18,744 shares

Grant/Award 1 txn

Insider Freeman Chris

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	18,744	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 18,744 contracts (Direct)

Footnotes (2)

1. F1. This represents a restricted stock unit award granted on March 11, 2026 that vests over a three-year period. 33% of the shares subject to such award will vest on April 1, 2027 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
2. F2. Not applicable for Restricted Stock Units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Guardant Health (GH) disclose for Chris Freeman?

Guardant Health disclosed that Chief Commercial Officer Chris Freeman received a grant of 18,744 restricted stock units. These RSUs are a stock-based compensation award and do not involve an open-market stock purchase or sale by the executive.

How many restricted stock units were granted to the GH Chief Commercial Officer?

Chris Freeman, Guardant Health’s Chief Commercial Officer, was granted 18,744 restricted stock units. Each RSU represents a right to receive one share of common stock if the applicable vesting conditions are satisfied over the grant’s three-year schedule.

What is the vesting schedule for Chris Freeman’s 18,744 RSUs at GH?

The 18,744 RSUs granted to Chris Freeman vest over three years. Thirty-three percent vest on April 1, 2027, and the remaining 67% vest in equal quarterly installments during the subsequent two-year period, subject to continued service and applicable conditions.

Does the Guardant Health Form 4 for Chris Freeman reflect a stock purchase or sale?

The Form 4 reports a stock unit grant, not a market trade. Chris Freeman received 18,744 restricted stock units as compensation, meaning there was no open-market purchase or sale of Guardant Health common shares in this particular insider filing.

How many Guardant Health RSUs does Chris Freeman hold after this award?

Following this grant, Chris Freeman holds 18,744 restricted stock units in Guardant Health. These RSUs convert into common stock only as they vest over time, so they represent a future equity interest rather than currently tradable shares on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/13/2026 - 08:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Freeman Chris

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	03/11/2026		A		18,744		(1)	(2)	Common Stock	18,744	$0	18,744	D

Explanation of Responses:

1. This represents a restricted stock unit award granted on March 11, 2026 that vests over a three-year period. 33% of the shares subject to such award will vest on April 1, 2027 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Chris Freeman	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.